Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin

被引:21
|
作者
Joel, SP [1 ]
Papamichael, D
Richards, F
Davis, T
Aslanis, V
Chatelut, E
Locke, K
Slevin, ML
Seymour, MT
机构
[1] St Bartholomews Hosp, Dept Med Oncol, London EC1A 7BE, England
[2] Cookridge Hosp, Canc Res UK Med Oncol Unit, Leeds, W Yorkshire, England
[3] Univ Toulouse 3, F-31062 Toulouse, France
[4] Inst Claudius Regaud, Toulouse, France
关键词
D O I
10.1016/j.clpt.2004.03.008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Our objective was to investigate the influence of oxaliplatin on the pharmacokinetics of 5-fluorouracil (5FU) administered in a bolus plus infusional regimen. Patients and Methods. All patients had advanced/metastatic colorectal cancer. In study 1, 19 patients were studied after bolus (400 mg/m(2)) plus a 22-hour infusion (600 mg/m(2)) of 5FU/leucovorin in the standard de Gramont regimen or the same regimen with oxaliplatin (85 mg/m(2)) given before 5FU. In study 2, 12 patients were studied for 2 treatment cycles, with 5FU given in a modified de Gramont regimen comprising bolus (400 mg/m(2)) plus a 46-hour infusion (2400 mg/m(2)) of 5FU. During 1 of these cycles, oxaliplatin (85 mg/m(2)) was given before 5FU. Results. The coadministration of oxaliplatin did not significantly alter 5FU area under the plasma concentration-time curve from 0 to 1 hour, area under the plasma concentration-time curve from time 0 to the last time point, or steady-state concentration in either the de Gramont (11.6 +/- 3.8 mg/L (.) h(-1), 14.9 +/- 4.2 mg (.) h/L, and 0.17 +/- 0.06 mg/L, respectively, for 5FU alone versus 9.4 +/- 2.6 mg/L (.) h(-1), 13.3 +/- 2.3 mg (.) h/L, and 0.16 +/- 0.04, respectively, for 5FU plus oxaliplatin) or modified de Gramont regimens (13.4 +/- 2.2 mg (.) h/L, 35.4 +/- 4.2 mg (.) h/L, and 0.46 +/- 0.08 mg/L, respectively, for 5FU alone versus 13.9 +/- 3.3 mg (.) h/L, 38.1 +/- 7.4 mg (.) h/L, and 0.53 +/- 0.12, respectively, for 5FU plus oxaliplatin). The inclusion of oxaliplatin coadministration as a covariate in a NONMEM analysis did not result in any change in the objective function or mean values for the following derived parameters: maximum velocity (1590 mg (.) h(-1)), day 1 Michaelis-Menten constant (7.8 mg (.) h(-1)), and day 2 Michaelis-Menten constant (11.9 mg (.) h(-1)). Conclusions. The coadministration of oxaliplatin in either the standard or modified de Gramont regimen does not significantly affect the pharmacokinetics of 5FU.
引用
收藏
页码:45 / 54
页数:10
相关论文
共 50 条
  • [21] PHARMACOKINETIC STUDIES OF 5-FLUOROURACIL IN RABBIT PLASMA
    Nasir, Bushra
    Ranjha, Nazar Muhammad
    Hanif, Muhammad
    Nasir, Saira
    Abbas, Ghulam
    Afzal, Samina
    Rashid, Sheikh Abdur
    Iqbal, Furqan
    ACTA POLONIAE PHARMACEUTICA, 2017, 74 (05): : 1573 - 1578
  • [22] In-vitro schedule-dependent interaction between oxaliplatin and 5-fluorouracil in human gastric cancer cell lines
    Qin, Baoli
    Tanaka, Risa
    Shibata, Yoshihiro
    Arita, Shuji
    Ariyama, Hiroshi
    Kusaba, Hitoshi
    Baba, Eishi
    Harada, Mine
    Nakano, Shuji
    ANTI-CANCER DRUGS, 2006, 17 (04) : 445 - 453
  • [23] Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer
    I Chau
    A Webb
    D Cunningham
    M Hill
    J S Waters
    A Norman
    A Massey
    British Journal of Cancer, 2001, 85 : 1258 - 1264
  • [24] Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer
    Chau, I
    Webb, A
    Cunningham, D
    Hill, M
    Waters, JS
    Norman, A
    Massey, A
    BRITISH JOURNAL OF CANCER, 2001, 85 (09) : 1258 - 1264
  • [25] Electrochemical and spectroscopic studies on interaction between DNA and 5-fluorouracil
    Ge Cun-Wang
    Wang Nan-Ping
    Gu Ning
    ACTA CHIMICA SINICA, 2006, 64 (17) : 1837 - 1842
  • [26] Theoretical Study on Hydrogen Interaction between 5-Fluorouracil and Glycine
    和芹
    霍爱新
    孟祥军
    杨静
    结构化学, 2010, 29 (05) : 738 - 746
  • [27] Theoretical Study on Hydrogen Interaction between 5-Fluorouracil and Glycine
    He Qin
    Huo Ai-Xin
    Meng Xiang-Jun
    Yang Jing
    CHINESE JOURNAL OF STRUCTURAL CHEMISTRY, 2010, 29 (05) : 738 - 746
  • [28] Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients
    Gamelin, E
    LeBouil, A
    BoisdronCelle, M
    Turcant, A
    Delva, R
    Cailleux, A
    Krikorian, A
    Brienza, S
    Cvitkovic, E
    Robert, J
    Larra, F
    Allain, P
    CLINICAL CANCER RESEARCH, 1997, 3 (06) : 891 - 899
  • [29] INTERACTION OF 5-FLUOROURACIL WITH SODIUM CARBOXYMETHYLCELLULOSE
    NISHIDA, K
    ANDO, Y
    ENOMOTO, M
    COLLOID AND POLYMER SCIENCE, 1982, 260 (05) : 511 - 513
  • [30] Pulmonary Fibrosis Under Chemotherapy with Oxaliplatin, 5-fluorouracil, and Leucovorin
    Jung, Jin Yong
    Hur, Gyu Young
    Jung, Ki Hwan
    Jung, Hae Chul
    Lee, Sung Yong
    Choi, In Keun
    Lee, Sang Yeub
    Kim, Je Hyeong
    Seo, Jae Hong
    Shin, Chol
    Shim, Jae Jeong
    In, Kwang Ho
    Kang, Kyung Ho
    Yoo, Se Hwa
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2005, 59 (05) : 536 - 540